

Health Care: Drugs
Pacific Biosciences of California Inc. (PACB: NASDAQ)
$2.42 -0.05 | -2.02%
05/17/13 - 04:00 PM ET
239.27K / 408.00K
Vol / Avg. Vol:
2.48 / 2.47
Open / Prev. Close:
2.34 - 2.48
Today's Range:
Portfolios with PACB
Latest PACB Headlines from TheStreet
More Financial News for PACB
Press Releases for PACB
- Rigrodsky & Long, P.A. Announces Class Action Asserting Violations Of The Federal Securities Laws By Pacific Biosciences Of California, Inc. - Business Wire 12.10.12 | 01:12 pm
- Nature Biotechnology Publications Showcase Value Of PacBio RS In De Novo Genome Assembly - Business Wire 07.02.12 | 07:07 am
- Pacific Biosciences Releases Software To Detect DNA Base Modifications Using The PacBio® RS - Business Wire 06.18.12 | 07:06 am
- The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Pacific Biosciences Of California, Inc. Of Class Action Lawsuit And The Deadline Of February 27, 2012 To Seek A Lead Plaintiff Position - Business Wire 02.16.12 | 02:02 pm
- PacBio® RS Compatible Products Now Available Through Pacific Biosciences Partner Program - Business Wire 02.15.12 | 07:02 am
- Pacific Biosciences Releases Next Generation Chemistry And Software For PacBio® RS DNA Sequencing System - Business Wire 02.13.12 | 07:02 am
- Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Pacific Biosciences Of California, Inc. - Business Wire 01.06.12 | 06:01 pm
- Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer - Business Wire 01.06.12 | 12:01 pm
- The Law Firm Of Levi & Korsinsky Notifies Investors With Losses On Their Investment In Pacific Biosciences Of California, Inc. Of Class Action Lawsuit And The Deadline Of February 27, 2012 To Seek A Lead Plaintiff Position - Business Wire 01.05.12 | 05:01 pm
- Rigrodsky & Long, P.A. Files Securities Fraud Class Action Lawsuit Against Pacific Biosciences Of California, Inc. - Business Wire 12.28.11 | 06:12 pm
See All Press Releases
Partner Headlines for PACB